Professional
Added to YB: 2025-01-30
Pitch date: 2025-01-29
MRNA [neutral]
Moderna, Inc.
-27.73%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$10.2B
Pitch Price
$41.40
Price Target
51.00 (+73%)
Dividend
N/A
EV/EBITDA
-1.16
P/E
-3.47
EV/Sales
1.10
Sector
Biotechnology
Category
turnaround
Show full summary:
Goldman Sachs Downgrades Moderna (MRNA) to Neutral, Slashes PT to $51
MRNA: Goldman downgrades to Neutral, PT $51 from $99. Lowered revenue guidance, cash breakeven delayed to 2029. Elevated expenses, potential equity offerings. Promising pipeline (INT, CF, CMV, norovirus) but quiet 2025 catalysts. Monitoring strategy, cash management, and execution.
Read full article (1 min)